Risdiplam (EvrysdiTM), as an oral RNA splicing modifier targeting SMN2, has been approved for the treatment of patients with SMA or a clinical diagnosis of SMA type 1, 2 or 3 or 1–4 SMN2 copies (EU) [26, 27]. Here, SMN2 is linked to spinal muscular atrophy, type 1.